The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrilethat are useful in the modulation of Janus kinase activity and are useful in thetreatment of diseases related to activity of Janus kinases including, for example,immune-related diseases, skin disorders, myeloid proliferative disorders,cancer, and other diseases.